StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $57.91 | $59.00 | +1.88% | 0.0M |
| 05-15 | $57.92 | $53.78 | -7.15% | 0.0M |
| 05-18 | $52.60 | $51.41 | -2.26% | 0.1M |
| 05-19 | $51.53 | $48.25 | -6.37% | 0.1M |
| 05-20 | $49.89 | $51.52 | +3.26% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-36.51M | $-25.41M | $-17.18M | $-14.49M |
Net Income | $-38.97M | $-24.32M | $-16.11M | $-14.04M |
EPS (Diluted) | $-50.83 | $-41.25 | $-27.36 | $-23.95 |
Total Assets | $53.02M | $15.31M | $21.82M | $31.65M |
Total Liabilities | $10.51M | $9.93M | $8.64M | $16.32M |
Cash & Equivalents | $48.91M | $10.67M | $16.39M | $25.61M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | $-12.73M |
Shares Outstanding | 1.37M | 563.49K | 563.04K | 42.23M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.